Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment

References

• Looker AC, Borrud LG, Dawson-Hughes B, et al. Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005–2008. NCHS Data Brief 2012;93:1-8
   PubMedGoogle Scholar
• MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148(3):197-213
   PubMed Web of Science ®Google Scholar
• Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008. J Bone Miner Res 2011;26:3-11
   PubMed Web of Science ®Google Scholar
• Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122(2 Suppl):S3-13
   PubMed Web of Science ®Google Scholar
• Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 2012;50:870-5
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yun H, Lange JL, et al. Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. Arthritis Care Res (Hoboken) 2012;64:1855-63
   PubMed Web of Science ®Google Scholar
• Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391-401
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Adachi JD, Rampakakis E, et al. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 2012;27:202-10
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Ross S, Samuels E, Gairy K, et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 2011;14:571-81
   PubMed Web of Science ®Google Scholar
• Díez-Pérez A, Gonzalez-Macias J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 2008;19:1511-16
   PubMed Web of Science ®Google Scholar
• Díez-Pérez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporos Int 2012;23:2769-74
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom 2003;6:307-14
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int 2008;19:1363-8
   PubMed Web of Science ®Google Scholar
• Optum Clinformatics Data Mart. Optum Insight, 2012. Available at: http://www.osteoporosistuminsight.com/life-sciences/solutions/value-strategy/marketing-analytics/clinformatics-data-mart/overview [Last accessed 6 May 2013]
   Google Scholar
• National Center for Health Statistics International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at: http://www.cdc.gov/nchs/icd/icd9cm.htm [Last accessed 6 May 2013]
   Google Scholar
• US Food and Drug Administration National Drug Code Directory. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm [Last accessed 6 May 2013]
   Google Scholar
• Orsini LS, Rousculp MD, Long SR, Wang S. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 2005;16:359-71
   PubMed Web of Science ®Google Scholar
• David C, Confavreux CB, Mehsen N, et al. Severity of osteoporosis: what is the impact of co-morbidities? Joint Bone Spine 2010;77(Suppl 2):S103-6
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Curtis JR, Delzell E, Chen L, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res 2011;26:683-8
   PubMed Web of Science ®Google Scholar
• Nikitovic M, Solomon DH, Cadarette SM. Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis 2010;1:149-62
   Google Scholar
• Díez-Pérez A, Olmos JM, Nogues X, et al. Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 2012;27:817-24
   PubMed Web of Science ®Google Scholar
• Adami S, Isaia G, Luisetto G, et al. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int 2008;19:1219-23
   PubMed Web of Science ®Google Scholar
• Cooper C, Jakob F, Chinn C, et al. Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 2008;19:493-501
   PubMed Web of Science ®Google Scholar
• Jakob F, Marin F, Martin-Mola E, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 2006;99:531-43
   PubMed Web of Science ®Google Scholar
• Barbagallo M, Dominguez LJ, Maugeri D, et al. Quality of life in osteoporotic women with inadequate clinical response to antiresorptive drugs: results from the ICARO study. Aging Clin Exp Res 2007;19(3 Suppl):24-7
   PubMedGoogle Scholar
• Cummings SR, Cosman F, Eastell R, et al. Goal-directed treatment of osteoporosis. J Bone Miner Res 2013;28:433-8
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Flahive J, Hooven FH, et al. Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res 2011;26:2770-7
   PubMed Web of Science ®Google Scholar
• Kim SY, Schneeweiss S, Liu J, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 2010;12:R154
   PubMed Web of Science ®Google Scholar
• van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3104-12
   PubMed Web of Science ®Google Scholar
• Prieto-Alhambra D, Nogues X, Javaid MK, et al. An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis 2013;72:911-17
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf 2006;15:710-18
   PubMed Web of Science ®Google Scholar
• Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000;11:533-6
   PubMed Web of Science ®Google Scholar